Skip to main content
SpringerLink
Log in

Treatment and management of Helicobacter pylori infection

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Clinical and basic mechanisms of interaction between Helicobacter pylori and its host have been the subject of numerous publications in the past year. Two additional proton pump inhibitors (PPIs), esomeprazole and rabeprazole, have shown effectiveness in H. pylori eradication when combined with amoxicillin and clarithromycin, and esomeprazole has demonstrated its effectiveness with only one daily dose. Other important recent developments worldwide include evidencebased treatment guidelines established at a European consensus meeting, improved accuracy in the urea breath test and the stool antigen test, new recommendations for second-line therapy, and a greater understanding of antimicrobial resistance in treatment failure. In addition, new studies have confirmed that H. pylori infection and use of nonsteroidal antiinflammatory drugs or aspirin are the major causes of peptic ulcer disease and ulcer bleeding. This paper reviews the results of these studies and their implications for future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: Of importance Of major importance

  1. Malfertheiner P, Megraud F, O’Morain C, et al.: Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002, 16:167–180. This report updates the previous recommendations. Most of these recommendations are based on evidence from published studies, and some are based on the large clinical experience in Europe.

    Article  PubMed  CAS  Google Scholar 

  2. Axon A, Talley NJ, Veldhuyzen van Zanten SJO, eds.: pH-Hp: Implications for dsypepsia management: proceedings of a symposium held in Geneva, Switzerland on 5 December 1998. Gut 2002, 50(Suppl 4):iv2-iv78.

  3. Laine L, Schoenfeld P, Fennerty MB: Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. Ann Intern Med 2001, 134:361–369.

    PubMed  CAS  Google Scholar 

  4. Chiba N, Veldhuyze van Zanten SJO, Sinclair P, et al.: Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment. Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002, 324:1012–1018. This is the first prospective, controlled study that carefully evaluates whether H. pylori eradication is useful in uninvestigated dyspepsia. These findings suggest that the "test and treat" approach is useful in the primary care setting.

    Article  PubMed  CAS  Google Scholar 

  5. Wu JCY, Chan FKL, Ching JYL, et al.: Empirical treatment based on ’typical’ reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori. Gastrointest Endosc 2002, 55:461–465.

    Article  PubMed  Google Scholar 

  6. McColl KEL, Murray LS, Gillen D, et al.: Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. BMJ 2002, 324:999–1002.

    Article  PubMed  CAS  Google Scholar 

  7. Ladabaum U, Fendrick AM, Scheiman JM: Outcomes of initial noninvasive Helicobacter pylori testing in U.S. primary care patients with uninvestigated dyspepsia. Am J Gastroenterol 2001, 96:2051–2057.

    Article  PubMed  CAS  Google Scholar 

  8. Manes G, Balzano A, Iaquinto G, et al.: Accuracy of stool antigen test in posteradication assessment of Helicobacter pylori infection. Dig Dis Sci 2001, 46:2440–2444.

    Article  PubMed  CAS  Google Scholar 

  9. Vaira D, Vakil N, Menegatti M, et al.: The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002, 136:280–287.

    PubMed  CAS  Google Scholar 

  10. Houghton JM, Ramamoorthy R, Randya H, et al.: Human plasma is directly bactericidal against Helicobacter pylori in vitro, potentially explaining the decreased detection of Helicobacter pylori during acute upper GI bleeding. Gastrointest Endosc 2002, 55:11–16.

    Article  PubMed  Google Scholar 

  11. Laine L, Fennerty MB, Osato M, et al.: Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter doubleblind trials. Am J Gastroenterol 2000, 95:3393–3398.

    Article  PubMed  CAS  Google Scholar 

  12. Vakil N, Kovacs T, Ignatowicz W, et al.: Comparable H. pylori eradication rates in peptic ulcer disease and non-peptic ulcer disease patients treated with rabeprazole-based triple therapy [abstract]. Gastroenterology 2002, 122(Suppl):A586.

    Article  Google Scholar 

  13. Treiber G, Wittig J, Ammon S, et al.: Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication. Arch Intern Med 2002, 162:153–160.

    Article  PubMed  CAS  Google Scholar 

  14. Khan Z, Nair P, O’Shea C, et al.: Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study. Scand J Gastroenterol 2002, 37:144–147.

    Article  PubMed  CAS  Google Scholar 

  15. Hojo M, Miwa H, Nagahara A, Sato N: Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001, 36:690–700. This pooled analysis study examines the world’s literature on retreatment after failed H. pylori eradication and confirms the usefulness of quadruple therapy as second-line treatment for H. pylori infection.

    Article  PubMed  CAS  Google Scholar 

  16. Georgopoulos SD, Ladas SD, Karatapanis S, et al.: Effectiveness of two quadruple, tetracycline-or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002, 16:569–575. This group of investigators tested the efficacy of two quadruple therapies to eradicate H. pylori infection after initial treatment failure. An interesting finding was that clarithromycin did not perform as well as tetracycline.

    Article  PubMed  CAS  Google Scholar 

  17. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB: Management of Helicobacter pylori eradication: the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002, 53:163–171.

    Article  PubMed  CAS  Google Scholar 

  18. Meyer JM, Silliman NP, Wang W, et al.: Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med 2002, 136:13–24.

    PubMed  Google Scholar 

  19. Bjorkholm B, Sjolund M, Falk PG, et al.: Mutation frequency and biological cost of antibiotic resistance in H. pylori. Proc Natl Acad Sci U S A 2001, 98:14607–14612.

    Article  PubMed  CAS  Google Scholar 

  20. Trieber CA, Taylor DE: Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 2002, 184:2131–2140. This is the first description of the molecular mechanism of tetracycline resistance in H. pylori.

    Article  PubMed  CAS  Google Scholar 

  21. Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784–789. H. pylori infection is clearly a causal mechanism for gastric cancer development in this Japanese study. This report makes a good case for eradication of H. pylori infection in those individuals who are at risk.

    Article  PubMed  CAS  Google Scholar 

  22. Kokkola A, Sipponen P, Rautelin H, et al.: The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002, 16:515–520.

    Article  PubMed  CAS  Google Scholar 

  23. Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal antiinflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359:14–22. This careful meta-analysis indicates that H. pylori infection and NSAIDs have a synergistic role in NSAID-related ulcer and ulcer complications.

    Article  PubMed  CAS  Google Scholar 

  24. Yoshida N, Sugimoto N, Hirayama F, et al.: Helicobacter pylori infection potentiates aspirin induced gastric mucosal injury in Mongolian gerbils. Gut 2002, 50:594–598.

    Article  PubMed  CAS  Google Scholar 

  25. Chan FKL, To KF, Wu JCY, et al.: Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002, 359:9–13.

    Article  PubMed  CAS  Google Scholar 

  26. Chan FKL, Chung SC, Suen BY, et al.: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967–973. Eradication of H. pylori infection is compared with PPI maintenance therapy in preventing ulcer rebleeding in aspirin and NSAID users in this prospective study from Hong Kong. H. pylori eradication and PPI maintenance seem to be similar in aspirin users, but PPI maintenance was superior in the patients on NSAIDs (naproxen). Different mechanisms appear to be operative in aspirin and NSAIDs.

    Article  PubMed  CAS  Google Scholar 

  27. Lanas A, Fuentes J, Benito R, et al.: Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002, 16:779–786. The fact that both low-dose aspirin and H. pylori infection are important in upper gastrointestinal bleeding is confirmed in this study. This study and that of Chan et al. remind us that aspirin is not a benign drug. The H. pylori-infected patient is particularly at risk.

    Article  PubMed  CAS  Google Scholar 

  28. Singh RK, McMahon AD, Patel H, et al.: Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease. Heart 2002, 88:43–46.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Section, Veterans Administration Salt Lake City Health Care System, 500 Foothill Boulevard (111G), 84148, Salt Lake City, UT, USA

    Mae F. Go MD

Authors
  1. Mae F. Go MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Go, M.F. Treatment and management of Helicobacter pylori infection. Curr Gastroenterol Rep 4, 471–477 (2002). https://doi.org/10.1007/s11894-002-0023-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-002-0023-1

Keywords

Search

Navigation